Anavex Life Sciences, a New York-based biopharmaceutical company, develops therapeutics for neurodegenerative diseases and employs 40 staff. Its lead compound, ANAVEX 2-73, targets Alzheimer's and Parkinson's diseases.
Anavex Life Sciences (AVXL) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Anavex Life Sciences's actual EPS was -$0.16, missing the estimate of -$0.15 per share, resulting in a -9.44% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
